Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook

Stock Track

02-28

Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.

The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.

For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:

Adding over 80 new clients, including its first national health plan partner, Cigna.
Expanding services offerings in areas like maternity, postpartum, and menopause.
Retaining 99% of existing clients, reflecting high satisfaction.
Continued investments in digital assets and product development.

While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1197750619"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197750619\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1197750619?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197750619","market":"hk","top_or_hot":-1,"title":"Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook","media":"Stock Track","content":"<p>Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.</p>\n\n<p>The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.</p>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:</p>\n\n<ul>\n<li>Adding over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanding services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retaining 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.</p>\n\n<p>The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.</p>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:</p>\n\n<ul>\n<li>Adding over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanding services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retaining 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGNY","symbol_name":"Progyny","start_time":0,"source_url":"","article_id":"1197750619","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197750619","pubTimestamp":1740753519,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Progyny  stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.For the full year 2024, Progyny's reve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGNY":"Progyny"},"translate_title":"股票跟踪Progyny飙升16%，第四季度盈利超出预期推动强劲增长前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1},"content_text":"Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.\nThe fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.\nFor the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:\n\nAdding over 80 new clients, including its first national health plan partner, Cigna.\nExpanding services offerings in areas like maternity, postpartum, and menopause.\nRetaining 99% of existing clients, reflecting high satisfaction.\nContinued investments in digital assets and product development.\n\nWhile Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}